PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors

被引：10

作者：

Minari, Roberta ^{[1
]}

Bonatti, Francesco ^{[1
]}

Mazzaschi, Giulia ^{[1
,2
]}

Dodi, Alessandra ^{[2
]}

Facchinetti, Francesco ^{[1
,3
]}

Gelsomino, Francesco ^{[4
]}

Cinquegrani, Gloria ^{[2
]}

Squadrilli, Anna ^{[1
]}

Bordi, Paola ^{[1
]}

Buti, Sebastiano ^{[1
]}

Bersanelli, Melissa ^{[1
]}

Leonetti, Alessandro ^{[1
]}

Cosenza, Agnese ^{[1
]}

Ferri, Leonarda ^{[1
]}

Rapacchi, Elena ^{[1
]}

Quaini, Federico ^{[2
]}

Ardizzoni, Andrea ^{[4
]}

Tiseo, Marcello ^{[1
,2
]}

机构：

[1] Univ Hosp Parma, Med Oncol Unit, Via Gramsci 14, I-43126 Parma, Italy

[2] Univ Parma, Dept Med & Surg, Parma, Italy

[3] Univ Paris Saclay, Inst Gustave Roussy, Biomarqueurs Predictifs & Nouvelles Strategies Th, INSERM, Villejuif, France

[4] AOU Policlin S Orsola Malpighi, Med Oncol, Bologna, Italy

来源：

TUMORI JOURNAL | 2022年 / 108卷 / 01期

关键词：

NSCLC; immunotherapy; PD-L1; SNPs; biomarker; CELL LUNG-CANCER; POLYMORPHISMS; ASSOCIATION; NIVOLUMAB; DOCETAXEL; EXPRESSION; PROGNOSIS; GENE;

D O I：

10.1177/03008916211014954

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objective: To investigate the role of CTLA-4, PD-1 (programmed death-1), and PD-L1 (programmed death-ligand 1) single nucleotide polymorphisms (SNPs) in predicting clinical outcome of patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs). Methods: A total of 166 consecutive patients were included. We correlated SNPs with clinical benefit, progression-free survival, time to treatment failure, and overall survival and evaluated the incidence of SNPs in nonresponder and long clinical benefit groups. Results: Considering the entire cohort, no correlation was found between SNPs and clinical outcome; however, PD-L1 rs4143815 SNP and the long clinical benefit group showed a statistically significant association (p = 0.02). The nonresponder cohort displayed distinctive PD-L1 haplotype (p = 0.05). Conclusion: PD-L1 SNPs seem to be marginally involved in predicting clinical outcome of NSCLC treated with ICI, but further investigations are required.

引用

页码：47 / 55

页数：9

共 31 条

[21] Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial [J].

Rittmeyer, Achim ;

Barlesi, Fabrice ;

Waterkamp, Daniel ;

Park, Keunchil ;

Ciardiello, Fortunato ;

von Pawel, Joachim ;

Gadgeel, Shirish M. ;

Hida, Toyoaki ;

Kowalski, Dariusz M. ;

Dols, Manuel Cobo ;

Cortinovis, Diego L. ;

Leach, Joseph ;

Polikoff, Jonathan ;

Barrios, Carlos ;

Kabbinavar, Fairooz ;

Frontera, Osvaldo Aren ;

De Marinis, Filippo ;

Turna, Hande ;

Lee, Jong-Seok ;

Ballinger, Marcus ;

Kowanetz, Marcin ;

He, Pei ;

Chen, Daniel S. ;

Sandler, Alan ;

Gandara, David R. .

LANCET, 2017, 389 (10066) :255-265

[22] Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer [J].

Rizvi, Naiyer A. ;

Hellmann, Matthew D. ;

Snyder, Alexandra ;

Kvistborg, Pia ;

Makarov, Vladimir ;

Havel, Jonathan J. ;

Lee, William ;

Yuan, Jianda ;

Wong, Phillip ;

Ho, Teresa S. ;

Miller, Martin L. ;

Rekhtman, Natasha ;

Moreira, Andre L. ;

Ibrahim, Fawzia ;

Bruggeman, Cameron ;

Gasmi, Billel ;

Zappasodi, Roberta ;

Maeda, Yuka ;

Sander, Chris ;

Garon, Edward B. ;

Merghoub, Taha ;

Wolchok, Jedd D. ;

Schumacher, Ton N. ;

Chan, Timothy A. .

SCIENCE, 2015, 348 (6230) :124-128

[23] Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction [J].

Shi, Xiao-Lei ;

Mancham, Shanta ;

Hansen, Bettina E. ;

de Knegt, Robert J. ;

de Jonge, Jeroen ;

van der Laan, Luc J. W. ;

Rivadeneira, Fernando ;

Metselaar, Herold J. ;

Kwekkeboom, Jaap .

JOURNAL OF HEPATOLOGY, 2016, 64 (06) :1274-1282

[24] Cancer statistics, 2020 [J].

Siegel, Rebecca L. ;

Miller, Kimberly D. ;

Jemal, Ahmedin .

CA-A CANCER JOURNAL FOR CLINICIANS, 2020, 70 (01) :7-30

[25] Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC [J].

Socinski, M. A. ;

Jotte, R. M. ;

Cappuzzo, F. ;

Orlandi, F. ;

Stroyakovskiy, D. ;

Nogami, N. ;

Rodriguez-Abreu, D. ;

Moro-Sibilot, D. ;

Thomas, C. A. ;

Barlesi, F. ;

Finley, G. ;

Kelsch, C. ;

Lee, A. ;

Coleman, S. ;

Deng, Y. ;

Shen, Y. ;

Kowanetz, M. ;

Lopez-Chavez, A. ;

Sandler, A. ;

Reck, M. ;

Ahualli, A. ;

Jarchum, G. ;

Kaen, D. L. ;

Kahl, S. ;

Kotliar, M. ;

Kowalyszyn, R. D. ;

Lerzo, G. ;

Magri, I ;

Martin, C. ;

Pastor, A. ;

Picon, P. ;

Streich, G. ;

Varela, M. ;

Blinman, P. ;

Boyer, M. ;

Crombie, C. ;

Gauden, S. ;

Gill, S. ;

Hughes, B. ;

John, T. ;

Joshi, A. ;

Kosmider, S. ;

Lewis, C. ;

Millward, M. ;

Nordman, I ;

Nott, L. ;

O'Byrne, K. ;

Parnis, F. ;

Potasz, N. ;

Richardson, G. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (24) :2288-2301

[26] CTLA-4+49A>G Polymorphism Is Associated with Advanced Non-Small Cell Lung Cancer Prognosis [J].

Song, Bao ;

Liu, Yanbing ;

Liu, Jie ;

Song, Xianrang ;

Wang, Zhehai ;

Wang, Mingyu ;

Zhu, Yufang ;

Han, Jinxiang .

RESPIRATION, 2011, 82 (05) :439-444

[27] A polymorphism in the promoter region of PD-L1 serves as a binding-site for SP1 and is associated with PD-L1 overexpression and increased occurrence of gastric cancer [J].

Tao, Li-Hua ;

Zhou, Xin-Ru ;

Li, Fu-Chao ;

Chen, Qi ;

Meng, Fan-Yi ;

Mao, Yong ;

Li, Rui ;

Hua, Dong ;

Zhang, Hong-Jian ;

Wang, Wei-Peng ;

Chen, Wei-Chang .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2017, 66 (03) :309-318

[28] A frequent somatic mutation in CD274 3'-UTR leads to protein over-expression in gastric cancer by disrupting miR-570 binding [J].

Wang, Weipeng ;

Sun, Jing ;

Li, Fang ;

Li, Rui ;

Gu, Yongping ;

Liu, Cuiping ;

Yang, Peng ;

Zhu, Ming ;

Chen, Lujun ;

Tian, Wenyan ;

Zhou, Huan ;

Mao, Yong ;

Zhang, Liang ;

Jiang, Jingting ;

Wu, Changping ;

Hua, Dong ;

Chen, Weichang ;

Lu, Binfeng ;

Ju, Jingfang ;

Zhang, Xueguang .

HUMAN MUTATION, 2012, 33 (03) :480-484

[29] Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial [J].

West, Howard ;

McCleod, Michael ;

Hussein, Maen ;

Morabito, Alessandro ;

Rittmeyer, Achim ;

Conter, Henry J. ;

Kopp, Hans-Georg ;

Daniel, Davey ;

McCune, Steven ;

Mekhail, Tarek ;

Zer, Alona ;

Reinmuth, Niels ;

Sadiq, Ahad ;

Sandler, Alan ;

Lin, Wei ;

Lohmann, Tania Ochi ;

Archer, Venice ;

Wang, Lijia ;

Kowanetz, Marcin ;

Cappuzzo, Federico .

LANCET ONCOLOGY, 2019, 20 (07) :924-937

[30] Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma [J].

Yeo, Min-Kyung ;

Choi, Song-Yi ;

Seong, In-Ock ;

Suh, Kwang-Sun ;

Kim, Jin Man ;

Kim, Kyung-Hee .

HUMAN PATHOLOGY, 2017, 68 :103-111

← 1 2 3 4 →